Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582113 · ClinicalTrials.gov registry record · Early Phase 1
Cognizin Citicoline Dosing in a Healthy Adolescent Male Population
A Early Phase 1 study of Neurocognitive Improvement, sponsored by Deborah Yurgelun-Todd.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT01582113: Completed Early Phase 1 study of Neurocognitive Improvement, sponsored by Deborah Yurgelun-Todd.
NCT01582113 is a Early Phase 1 study of Neurocognitive Improvement that has completed, run by Deborah Yurgelun-Todd. The registered enrollment target is 84 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582113, a Early Phase 1 study of Neurocognitive Improvement, has completed, sponsored by Deborah Yurgelun-Todd.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the functional effects of Citicoline, a natural supplement, when administered for a duration of four weeks (28 days) to non-psychiatric adolescent male participants. The investigators hypothesize that citicoline will provide cognitive benefits to this population after 28 days of supplementation.
Primary Outcome
Using baseline assessment measures gathered at Visit 1, assessments collected at Visits 2 and 3 will be used to determine whether the combined administration of citicoline will improve neurocognitive performance in male adolescents.
Conditions Studied
Interventions
- DRUG Citicoline
- OTHER Microcrystalline Cellulose
Study Locations (1)
Utah
- The Brain Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-05-24 |
| Phase | Early Phase 1 |
What the finished NCT01582113 record still lists
NCT01582113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (58% higher).
The record links to 1 condition, with Neurocognitive Improvement appearing as the primary indexed condition, and to 2 interventions - of which Citicoline is the first listed.
NCT01582113 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT01582113 about?
NCT01582113 is a clinical study titled "Cognizin Citicoline Dosing in a Healthy Adolescent Male Population". To determine the functional effects of Citicoline, a natural supplement, when administered for a duration of four weeks (28 days) to non-psychiatric adolescent male participants. The investigators hypothesize that citicoline will provide cognitive benefits to this population after 28 days of supplem...
What is the current status of trial NCT01582113?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 84 participants. The study started on 2012-06. Estimated completion is 2017-05-24.
What conditions does trial NCT01582113 study?
This clinical trial studies the following conditions: Neurocognitive Improvement.
What interventions are being tested in trial NCT01582113?
The interventions under investigation include: Citicoline (DRUG), Microcrystalline Cellulose (OTHER).
Who is sponsoring clinical trial NCT01582113?
This trial is sponsored by Deborah Yurgelun-Todd, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01582113 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01582113's enrollment target sits among peer trials
84 261st of 2000 higher than 1,738 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia